Skip to main content
Equibles
ATRA logo

ATRA · Atara Biotherapeutics, Inc.

Track ATRA — free

Use ATRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ATRA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.09 -0.42 (-4.94%) At close · Aug 14
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”
View the 10-Q filed Aug 12, 2026
Market Cap
$81.21M
Shares
10.04M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.09 Open$8.51 Day$7.99–8.51 52W close$4.18–18.09 Avg vol 30d70K Short int537K · 5.3% float · 9.4d Short vol33% Last earningsNov 1, 2023 DataJun 2024–Aug 2026 Filing10-Q · Aug 12

Raw chart and full-history price indicators begin at the captured split on Jun 20, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −14%
below
RSI (14) 43
neutral
MACD trend Positive
52-week position 28%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Neutral
1-month return −4%
trailing
6-month return +93%
trailing
YTD return −55%
this year
Relative strength +79%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $9 › 200d $9 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +4 funds added
Insider flow Distributing
Net -$69.9K over 90 days · 100% sells
Short interest Falling
5.35% of float · ▼ -7.1% MoM · 9.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
37 holders — mid 3-yr range
Squeeze score 57
elevated · 0–100
Fundamentals
Fair
Revenue growth −6%
Y/Y
EPS growth +123%
Y/Y
Free cash flow $-50.9M
Balance sheet $8.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 144%
annualized · 1-yr
Max drawdown −77%
past year
ATR 8.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
43 Neutral
MACD trend
Positive Bullish
52-week position
28% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $9 › 200d $9 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +4 funds added
Insider flow Distributing
Net -$69.9K over 90 days · 100% sells
Short interest Falling
5.35% of float · ▼ -7.1% MoM · 9.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
37 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4 Now $8 · 28% Range high $18
vs 200-day avg -11% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATRA
Atara Biotherapeutics, Inc.
this stock
$81.21M -55.3% -6.3% — 5.3%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
37
% held
44.5%
Net QoQ
+1.9M sh
Top holder
EcoR1 Capital, LLC
Held Float
View
Held by Funds
Fund positions
22
View
Short & Settlement
Short Interest Falling
Shares short
536.9K
Days to cover
9.4d
Change
-40.7K sh
View
Short Volume
Short vol %
33%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
974
Value
$9.5K
As of
Jul 13, 2026
View
Off-Exchange
Off-exchange %
29.0%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$69.9K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$120.8M
Net income (FY)
$32.7M
EPS diluted
$2.57
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
16
View
Proposed Sales
Value
$28.9K
Shares
2.8K
Filed
May 18, 2026
View
Earnings & Events
Earnings Calls
Last call
Nov 1, 2023
View

Performance

Raw-price comparisons begin at the captured split on Jun 20, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
ATRA -4.3% -3.6% +92.6% -3.5% -55.3%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -4.7% -8.0% +78.9% -7.4% -69.1%
Key facts CIK 1604464 CUSIP 046513206 13F (30d) 38 filings 36 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)